JP5774982B2 - イミダゾ［１，２−ａ］ピリジン化合物 - Google Patents

イミダゾ［１，２−ａ］ピリジン化合物 Download PDF

Info

Publication number
JP5774982B2
JP5774982B2 JP2011510650A JP2011510650A JP5774982B2 JP 5774982 B2 JP5774982 B2 JP 5774982B2 JP 2011510650 A JP2011510650 A JP 2011510650A JP 2011510650 A JP2011510650 A JP 2011510650A JP 5774982 B2 JP5774982 B2 JP 5774982B2
Authority
JP
Japan
Prior art keywords
methyl
group
imidazo
substituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011510650A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011523945A5 (cg-RX-API-DMAC7.html
JP2011523945A (ja
Inventor
ケヴィン ファン，クン
ケヴィン ファン，クン
シンヘ ウ，フランク
シンヘ ウ，フランク
ティー． グローヴァー，ポール
ティー． グローヴァー，ポール
シー． ホプキンス，セス
シー． ホプキンス，セス
キャンベル，ウナ
シチル，ミラン
エル． スピア，ケリー
エル． スピア，ケリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of JP2011523945A publication Critical patent/JP2011523945A/ja
Publication of JP2011523945A5 publication Critical patent/JP2011523945A5/ja
Application granted granted Critical
Publication of JP5774982B2 publication Critical patent/JP5774982B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2011510650A 2008-05-19 2009-05-19 イミダゾ［１，２−ａ］ピリジン化合物 Active JP5774982B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5443208P 2008-05-19 2008-05-19
US5443708P 2008-05-19 2008-05-19
US61/054,432 2008-05-19
US61/054,437 2008-05-19
PCT/US2009/044525 WO2009143156A2 (en) 2008-05-19 2009-05-19 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015090193A Division JP6211556B2 (ja) 2008-05-19 2015-04-27 イミダゾ［１，２−ａ］ピリジン化合物

Publications (3)

Publication Number Publication Date
JP2011523945A JP2011523945A (ja) 2011-08-25
JP2011523945A5 JP2011523945A5 (cg-RX-API-DMAC7.html) 2012-07-05
JP5774982B2 true JP5774982B2 (ja) 2015-09-09

Family

ID=41031732

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011510650A Active JP5774982B2 (ja) 2008-05-19 2009-05-19 イミダゾ［１，２−ａ］ピリジン化合物
JP2015090193A Active JP6211556B2 (ja) 2008-05-19 2015-04-27 イミダゾ［１，２−ａ］ピリジン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015090193A Active JP6211556B2 (ja) 2008-05-19 2015-04-27 イミダゾ［１，２−ａ］ピリジン化合物

Country Status (6)

Country Link
US (2) US8497278B2 (cg-RX-API-DMAC7.html)
EP (1) EP2300470A2 (cg-RX-API-DMAC7.html)
JP (2) JP5774982B2 (cg-RX-API-DMAC7.html)
AU (1) AU2009249186B2 (cg-RX-API-DMAC7.html)
CA (1) CA2724842A1 (cg-RX-API-DMAC7.html)
WO (1) WO2009143156A2 (cg-RX-API-DMAC7.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200918102A (en) * 2007-10-24 2009-05-01 Nihon Mediphysics Co Ltd Novel compound having affinity for amyloid
KR101774035B1 (ko) 2009-10-30 2017-09-01 얀센 파마슈티카 엔.브이. 이미다조［１，２―ｂ］피리다진 유도체 및 ＰＤＥ１０ 저해제로서의 그의 용도
EP3257854A1 (en) * 2009-11-05 2017-12-20 University of Notre Dame du Lac Imidazo[1,2-a]pyridine compounds, synthesis thereof, and methods of using same
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
CA2800618C (en) 2010-05-26 2018-08-28 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2012130322A1 (en) * 2011-03-31 2012-10-04 Elara Pharmaceuticals Gmbh Imidazo [1,2-a]pyridine compounds for use in therapy
EA027418B1 (ru) 2011-06-27 2017-07-31 Янссен Фармацевтика Нв ПРОИЗВОДНЫЕ 1-АРИЛ-4-МЕТИЛ[1,2,4]ТРИАЗОЛО[4,3-a]ХИНОКСАЛИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ ИХ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ
CA2869535A1 (en) * 2012-05-30 2013-12-05 F. Hoffmann-La Roche Ag Pyrrolidino heterocycles
ES2855575T3 (es) 2012-06-26 2021-09-23 Janssen Pharmaceutica Nv Combinaciones que comprenden compuestos de 4-metil-[1,2,4]triazolo[4,3-a]quinoxalina como inhibidores de PDE2 e inhibidores de PDE10 para su uso en el tratamiento de trastornos neurológicos o metabólicos
KR102171706B1 (ko) 2012-07-09 2020-10-30 얀센 파마슈티카 엔.브이. 포스포디에스테라아제 10 효소의 억제제
JP2016527184A (ja) 2013-05-24 2016-09-08 イオメット ファーマ リミテッド Ｓｌｃ２ａ輸送体阻害剤
PE20181352A1 (es) 2015-09-17 2018-08-22 Marvin J Miller Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias
PT3153506T (pt) * 2015-10-07 2018-03-22 Sanko Tekstil Isletmeleri San Ve Tic As Isoxazoles, um processo para a sua preparação e seus usos
WO2017070089A1 (en) 2015-10-19 2017-04-27 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170145025A1 (en) 2015-11-19 2017-05-25 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3007724C (en) 2015-12-10 2023-10-17 Bayer Pharma Aktiengesellschaft 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders
JP2018538296A (ja) 2015-12-10 2018-12-27 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ペルヒドロピロロ［３，４−ｃ］ピロール誘導体およびその使用
LT3394033T (lt) 2015-12-22 2021-03-10 Incyte Corporation Heterocikliniai junginiai, kaip imunomoduliatoriai
US20170320875A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
HRP20221030T1 (hr) 2016-06-20 2022-11-11 Incyte Corporation Heterociklički spojevi kao imunomodulatori
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
JOP20190005A1 (ar) 2016-07-20 2019-01-20 Bayer Ag مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها
CN106279123B (zh) * 2016-08-15 2018-09-04 郑州大学 3-(苯磺酰甲基)咪唑并杂环类化合物及其合成方法
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
EA039175B1 (ru) * 2016-12-14 2021-12-14 Байер Акциенгезельшафт Замещенные диазагетеробициклические соединения, способ их получения и их применение
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
JP7149276B2 (ja) 2016-12-22 2022-10-06 インサイト・コーポレイション Ｐｄ－ｌ１内在化誘導物質としてのテトラヒドロイミダゾ［４，５－ｃ］ピリジン誘導体
BR112019012993A2 (pt) 2016-12-22 2019-12-03 Incyte Corporation derivados de benzo-oxazol como imunomoduladores
CN107163039A (zh) * 2017-05-11 2017-09-15 浙江工业大学 一种6‑甲基‑2‑对甲苯基咪唑并[1,2‑a]吡啶‑3‑甲醛的制备方法
JOP20190284A1 (ar) 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
WO2018227427A1 (en) 2017-06-14 2018-12-20 Bayer Aktiengesellschaft Substituted bridged diazepane derivatives and use thereof
MY210070A (en) 2018-03-30 2025-08-25 Incyte Corp Heterocyclic compounds as immunomodulators
PT3790877T (pt) 2018-05-11 2023-05-10 Incyte Corp Derivados de tetrahidro-imidazo[4,5-c]piridina como imunomoduladores pd-l1
PE20210555A1 (es) * 2018-06-13 2021-03-17 Hoffmann La Roche Nuevos derivados de isoxazolil eter como pam de gaba a alfa5
CN110964020B (zh) * 2018-09-28 2022-06-14 中国科学院大连化学物理研究所 一种制备3’,4’-二氢螺[吲哚啉-3,2’-吡咯]化合物的方法
SG11202106706TA (en) * 2018-12-29 2021-07-29 Wuhan Ll Science And Technology Development Co Ltd Heterocyclic compound intermediate, preparation method therefor and application thereof
TW202115059A (zh) 2019-08-09 2021-04-16 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽
BR112022005826A2 (pt) 2019-09-30 2022-06-21 Incyte Corp Compostos de pirido[3,2-d]pirimidina como imunomoduladores
BR112022009031A2 (pt) 2019-11-11 2022-10-11 Incyte Corp Sais e formas cristalinas de um inibidor de pd-1/pd-l1
CN114380819B (zh) * 2020-10-22 2024-08-23 鲁南制药集团股份有限公司 一种唑吡坦中间体化合物
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
MX2023005362A (es) 2020-11-06 2023-06-22 Incyte Corp Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo.
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB991589A (en) * 1963-04-30 1965-05-12 Selvi & C Lab Bioterapico Novel [1,2-ª‡]imidazopyridines and a process for the manufacture thereof
US3489755A (en) * 1966-08-03 1970-01-13 Pfizer & Co C Imidazo (1,2-b) pyridazines
US4242513A (en) * 1979-03-05 1980-12-30 Appleton Papers Inc. Lactone compounds containing a heterocyclic radical
GB8305245D0 (en) * 1983-02-25 1983-03-30 Fujisawa Pharmaceutical Co Imidazo-heterocyclic compounds
FR2568880B1 (fr) * 1984-08-07 1986-12-12 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
ATE62687T1 (de) * 1986-01-22 1991-05-15 Synthelabo Acylaminomethylimidazo(1,2-a>pyrimidinderivate, ihre herstellung und therapeutische verwendung.
WO1989001333A1 (en) * 1987-08-07 1989-02-23 The Australian National University IMIDAZO[1,2-b]PYRIDAZINES
IN179789B (cg-RX-API-DMAC7.html) * 1992-02-10 1997-12-06 Council Scient Ind Res
FR2714907B1 (fr) * 1994-01-07 1996-03-29 Union Pharma Scient Appl Nouveaux dérivés de l'Adénosine, leurs procédés de préparation, compositions pharmaceutiques les contenant.
JPH09176165A (ja) * 1995-12-25 1997-07-08 Nippon Nohyaku Co Ltd イミダゾ［１，２−ａ］ピリジン誘導体、その製法およびその用途
US6552037B2 (en) * 2000-06-30 2003-04-22 Neurogen Corporation 2-Substituted imidazo[1,2-A]pyridine derivatives
US6514969B2 (en) * 2000-08-16 2003-02-04 Boehringer Ingelheim Pharma Kg β-amyloid inhibitors, processes for preparing them, and their use in pharmaceutical compositions
DE10040016A1 (de) * 2000-08-16 2002-02-28 Boehringer Ingelheim Pharma Neue beta-Amyloid Inhibitoren, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
SE0100567D0 (sv) * 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
DE602004029272D1 (de) * 2003-10-28 2010-11-04 Sepracor Inc Imidazoä1,2-aüpyridin-anxiolytika
WO2005080355A1 (en) * 2004-02-12 2005-09-01 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
RU2007121864A (ru) * 2004-11-11 2008-12-20 Феррер Интернасионал ИМИДАЗО[1,2-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), СПОСОБ ИХ ПОЛУЧЕНИЯ (ВАРИАНТЫ), КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С МОДУЛЯЦИЕЙ РЕЦЕПТОРОВ GABAA, ИЛИ α1-GABAA, ИЛИ α2-GABAA (ВАРИАНТЫ)
AU2006225355B2 (en) * 2005-03-21 2010-12-09 Helsinn Healthcare Sa Imidazo(1,2-a)pyridine derivatives: preparation and pharmaceutical applications
US7666880B2 (en) * 2005-03-21 2010-02-23 S*Bio Pte Ltd. Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications
AU2006254336B9 (en) 2005-06-01 2013-02-28 Ucb Pharma, S.A. 2 -oxo-I -pyrrolidine derivatives/ processes for preparing them and their therapeutic use on the central nervous system
AU2006278397B2 (en) * 2005-08-04 2013-01-17 Sirtris Pharmaceuticals, Inc. Oxazolopyridine derivatives as sirtuin modulators
AU2006322067A1 (en) * 2005-12-06 2007-06-14 Merck Sharp & Dohme Corp. Morpholine carboxamide prokineticin receptor antagonists
EP1845098A1 (en) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
EP2054060B1 (en) * 2006-08-24 2014-04-02 Australian Nuclear Science & Technology Organisation Fluorinated ligands for targeting peripheral benzodiazepine receptors
MX2009004700A (es) * 2006-11-06 2009-05-15 Supergen Inc Derivados de imidazo[1,2-b]piridazin y pirazolo[1,5-a] pirimidina y su uso como inhibidores de proteina cinasa.
EP1974729A1 (en) * 2007-03-28 2008-10-01 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms

Also Published As

Publication number Publication date
US8497278B2 (en) 2013-07-30
EP2300470A2 (en) 2011-03-30
AU2009249186A1 (en) 2009-11-26
US20110166146A1 (en) 2011-07-07
US20130289013A1 (en) 2013-10-31
WO2009143156A3 (en) 2010-01-14
JP2015180633A (ja) 2015-10-15
JP2011523945A (ja) 2011-08-25
JP6211556B2 (ja) 2017-10-11
WO2009143156A2 (en) 2009-11-26
AU2009249186B2 (en) 2014-05-22
CA2724842A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
JP6211556B2 (ja) イミダゾ［１，２−ａ］ピリジン化合物
JP5987005B2 (ja) オレキシン拮抗薬として有用な新規なピラゾール及びイミダゾール誘導体
AU2014324595B2 (en) Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
CA2905012C (en) Substituted 7-azabicycles and their use as orexin receptor modulators
TWI485151B (zh) 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
JP7577655B2 (ja) 環状尿素
EP4031552B1 (en) Azole-fused pyridazin-3(2h)-one derivatives
JP6964576B2 (ja) 置換４−アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用
EP2742049A1 (en) Tricyclic heterocyclic compounds and jak inhibitors
BR122019020716B1 (pt) heterociclilaminas como inibidores de pi3k e composição farmacêutica que as compreende
TW201000481A (en) Novel phenylimidazole derivatives as PDE10A enzyme inhibitors
JP2012514044A (ja) Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物
US20170107204A1 (en) Trka kinase inhibitors, compositions and methods thereof
JP2021529746A (ja) 心臓サルコメア阻害剤
TW202128677A (zh) Cd38抑制劑
US20170158698A1 (en) TrKA Kinase Inhibitors, Compositions and Methods Thereof
EP4251619A1 (en) Pyrrolidine derivatives and methods of use
JP2022507858A (ja) Ｉｒａｋ４阻害剤としての新規な三環式化合物
KR20150044897A (ko) 유약 x 증후군, 파킨슨병 또는 역류 질환의 치료에 유용한 디아제피논 유도체
JP7264833B2 (ja) ヘテロシクリルメチリデン誘導体およびｍＧｌｕＲ５受容体のモジュレーターとしてのそれらの使用
WO2025117662A1 (en) Heterocyclic compounds useful as kcnt1 inhibitors
CN118724895A (zh) 稠环胺类衍生物抑制剂、其制备方法和应用
CN118930527A (zh) 酰胺类衍生物调节剂、其制备方法和应用
HK40076219A (en) Azole-fused pyridazin-3(2h)-one derivatives
HK40076219B (en) Azole-fused pyridazin-3(2h)-one derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140317

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150427

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150609

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150702

R150 Certificate of patent or registration of utility model

Ref document number: 5774982

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250